An Interpretable Multitask Framework BiLAT Enables Accurate Prediction of Cyclin-Dependent Protein Kinase Inhibitors

被引:5
|
作者
Qian, Xu [1 ]
Dai, Xiaowen [1 ]
Luo, Lin [1 ]
Lin, Mingde [1 ]
Xu, Yuan [1 ]
Zhao, Yang [1 ]
Huang, Dingfang [1 ]
Qiu, Haodi [1 ]
Liang, Li [1 ]
Liu, Haichun [1 ]
Liu, Yingbo [1 ]
Gu, Lingxi [1 ]
Lu, Tao [1 ,2 ]
Chen, Yadong [1 ]
Zhang, Yanmin [1 ]
机构
[1] China Pharmaceut Univ, Sch Sci, Lab Mol Design & Drug Discovery, Nanjing 211198, Peoples R China
[2] China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R China
基金
中国国家自然科学基金;
关键词
CELL-CYCLE; CANCER; TARGETS; CDKS;
D O I
10.1021/acs.jcim.3c00473
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The cyclin-dependent protein kinases (CDKs) are protein-serine/threonine kinases with crucial effects on the regulation of cell cycle and transcription. CDKs can be a hallmark of cancer since their excessive expression could lead to impaired cell proliferation. However, the selectivity profile of most developed CDK inhibitors is not enough, which have hindered the therapeutic use of CDK inhibitors. In this study, we propose a multitask deep learning framework called BiLAT based on SMILES representation for the prediction of the inhibitory activity of molecules on eight CDK subtypes (CDK1, 2, 4-9). The framework is mainly composed of an improved bidirectional long short-term memory module BiLSTM and the encode layer of the Transformer framework. Additionally, the data enhancement method of SMILES enumeration is applied to improve the performance of the model. Compared with baseline predictive models based on three conventional machine learning methods and two multitask deep learning algorithms, BiLAT achieves the best performance with the highest average AUC, ACC, F1-score, and MCC values of 0.938, 0.894, 0.911, and 0.715 for the test set. Moreover, we constructed a targeted external data set CDK-Dec for the CDK family, which mainly contains bait values screened by 3D similarity with active compounds. This dataset was utilized in the subsequent evaluation of our model. It is worth mentioning that the BiLAT model is interpretable and can be used by chemists to design and synthesize compounds with improved activity. To further verify the generalization ability of the multitask BiLAT model, we also conducted another evaluation on three public datasets (Tox21, ClinTox, and SIDER). Compared with several currently popular models, BiLAT shows the best performance on two datasets. These results indicate that BiLAT is an effective tool for accelerating drug discovery.
引用
收藏
页码:3350 / 3368
页数:19
相关论文
共 50 条
  • [31] Discovery and Development of Cyclin-Dependent Kinase 8 Inhibitors
    Lv, Xiao
    Tian, Yongbing
    Li, Shiyu
    Cheng, Kai
    Huang, Xufeng
    Kong, Haiyan
    Liao, Chenzhong
    Xie, Zhouling
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (32) : 5429 - 5443
  • [32] Substituted aminobenzimidazole pyrimidines as cyclin-dependent kinase inhibitors
    Verma, S
    Nagarathnam, D
    Shao, JX
    Zhang, L
    Zhao, J
    Wang, YM
    Li, TD
    Mull, E
    Enyedy, I
    Wang, CG
    Zhu, QM
    Altieri, M
    Jordan, J
    Dang, TTA
    Reddy, S
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (08) : 1973 - 1977
  • [33] Cyclin-dependent kinase inhibitors and angiogenesis in sinonasal carcinomas
    Bottini, Consuelo
    Rossi, Valentina
    Valente, Guido
    Tessitore, Luciana
    CANCER RESEARCH, 2006, 66 (08)
  • [34] Novel potent pharmacological cyclin-dependent kinase inhibitors
    Wesierska-Gadek, Jozefa
    Chamrad, Ivo
    Krystof, Vladimir
    FUTURE MEDICINAL CHEMISTRY, 2009, 1 (09) : 1561 - 1581
  • [35] Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
    Giannone, Gaia
    Tuninetti, Valentina
    Ghisoni, Eleonora
    Genta, Sofia
    Scotto, Giulia
    Mittica, Gloria
    Valabrega, Giorgio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (09)
  • [36] Cyclin-dependent kinase inhibitors move into Phase III
    Malini Guha
    Nature Reviews Drug Discovery, 2012, 11 : 892 - 894
  • [37] Cyclin-dependent kinase inhibitors closer to market launch?
    Galons, Herve
    Oumata, Nassima
    Gloulou, Olfa
    Meijer, Laurent
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2013, 23 (08) : 945 - 963
  • [38] Expression of cyclin-dependent kinase inhibitors in vascular disease
    Tanner, FC
    Yang, ZY
    Duckers, E
    Gordon, D
    Nabel, GJ
    Nabel, EG
    CIRCULATION RESEARCH, 1998, 82 (03) : 396 - 403
  • [39] Functional analysis of cyclin-dependent kinase inhibitors of Arabidopsis
    De Veylder, L
    Beeckman, T
    Beemster, GTS
    Krols, L
    Terras, P
    Landrieu, I
    Van der Schueren, E
    Maes, S
    Naudts, M
    Inzé, D
    PLANT CELL, 2001, 13 (07): : 1653 - 1667
  • [40] ROLE OF THE CYCLIN-DEPENDENT KINASE INHIBITORS IN THE DEVELOPMENT OF CANCER
    HIRAMA, T
    KOEFFLER, HP
    BLOOD, 1995, 86 (03) : 841 - 854